Skip to content
Trial Eligibility
Menu

Lung Cancer Clinical Trials near Chicago, IL

143 studies for Lung Cancer are recruiting at 518 sites within 50 miles of Chicago, Illinois, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Lung Cancer trials in the US or all trials near Chicago.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Lung Cancer studies enrolling near Chicago

Showing the 50 nearest of 143 studies.
  1. Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

    NCT03851445

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    45 sites within 50 mi
  2. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    NCT06116682

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); Northwestern University (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    29 sites within 50 mi
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    NCT04267848

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    28 sites within 50 mi
  4. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    NCT06616584

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); Northwestern University (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    28 sites within 50 mi
  5. Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

    NCT05624996

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); Northwestern University (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    24 sites within 50 mi
  6. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

    NCT05642572

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); Northwestern University (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    22 sites within 50 mi
  7. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    NCT06096844

    • Phase 3
    • Ages 70 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); Rush MD Anderson Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    22 sites within 50 mi
  8. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    NCT04181060

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); University of Illinois (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    18 sites within 50 mi
  9. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    18 sites within 50 mi
  10. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    NCT06031688

    • Phase 2
    • Ages 18 Minutes and older
    • Sex: All

    Nearest sites: John H Stroger Jr Hospital of Cook County (Chicago, IL); Northwestern University (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    17 sites within 50 mi
  11. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); John H Stroger Jr Hospital of Cook County (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    17 sites within 50 mi
  12. LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

    NCT06073431

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Advocate Illinois Masonic Medical Center (Chicago, IL); Advocate Christ Medical Center (Oak Lawn, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 50 mi
  13. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: The University Of Chicago (Chicago, IL); UChicago Medicine - River East (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  14. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    NCT06498635

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); Loyola University Medical Center (Maywood, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  15. Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

    NCT06769126

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); Loyola University Medical Center (Maywood, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  16. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

    NCT06686771

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); Northwestern Medicine Oak Brook (Oak Brook, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  17. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    NCT07222566

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Illinois Cancer Specialists (Chicago, IL); University of Illinois Hospital and Health Sciences System (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  18. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    NCT07291037

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Chicago, IL); Research Site (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  19. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    NCT04613596

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago (Chicago, IL); Loyola University Medical Center (Maywood, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  20. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    NCT06287775

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Comprehensive Cancer Center (Chicago, IL); University of Chicago Medicine-Orland Park (Orland Park, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  21. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    NCT04302025

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); Northwestern Medicine Cancer Center Warrenville (Warrenville, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  22. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    NCT06293898

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medicine (Chicago, IL); University of Illinois Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  23. Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

    NCT06500481

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern University (Chicago, IL); Northwestern Medicine Cancer Center Warrenville (Warrenville, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  24. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    NCT06667076

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Rush University Medical Center Rush University Cancer Center Chicago (Chicago, IL); University of Illinois at Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  25. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    NCT06767514

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Clinical Study Site (Chicago, IL); Clinical Study Site (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  26. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    NCT06875310

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Illinois at Chicago (Chicago, IL); Illinois Cancer Specialists (Arlington Heights, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  27. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    NCT06890598

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medical Center (Chicago, IL); University of Illinois at Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  28. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    NCT07144280

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Illinois Cancer Specialists (Chicago, IL); Accellacare of Duly (Lisle, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  29. A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    NCT07154290

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Rush University Medical Center (Chicago, IL); University of Illinois Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  30. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    NCT05005403

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medical Center /ID# 276271 (Chicago, IL); University of Illinois Hospital and Health Sciences System /ID# 251750 (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  31. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    NCT05433142

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Xencor Investigative Site (Chicago, IL); Xencor Investigative Site (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  32. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    NCT05920356

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: University of Illinois Chicago (Chicago, IL); Illinois Cancer Specialists (Niles, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  33. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    NCT06119581

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Hospital (Chicago, IL); University of Illinois at Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  34. Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

    NCT06122077

    • Observational
    • Ages 50 years and older
    • Sex: All

    Nearest sites: University of Chicago (Chicago, IL); Walgreens (Deerfield, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  35. A Registry for People With Lung Cancer

    NCT06424327

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Rush University Medical Center (Data collection only) (Chicago, IL); Endeavor Health (Evanston, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  36. SMP-3124LP in Adults With Advanced Solid Tumors

    NCT06526819

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Northwestern Medicine Cancer Center (Chicago, IL); The University of Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  37. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    NCT06568939

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Illinois Hospital and Health Sciences System /ID# 275345 (Chicago, IL); Illinois Cancer Specialists /ID# 274678 (Niles, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  38. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

    NCT06627647

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Chicago, IL); Research Site (Hinsdale, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  39. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    NCT06692738

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Chicago, IL); Research Site (Hinsdale, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  40. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    NCT06881784

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Center for Care and Discovery (Chicago, IL); University of Illinois Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  41. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    NCT07185997

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Illinois Hospital and Health Sciences Systems (Chicago, IL); Illinois Cancer Specialists (Arlington Heights, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  42. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    NCT07195695

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Illinois Hospital and Health Sciences System (Chicago, IL); Duly Health and Care - Lisle (Lisle, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  43. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    NCT07361497

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medical Center (Chicago, IL); Endeavor Health (Evanston, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  44. A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

    NCT07365241

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Chicago Medical Center /ID# 280149 (Chicago, IL); City Of Hope - Chicago /ID# 281335 (Zion, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  45. LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

    NCT07408531

    • Interventional
    • Ages 50 to 80 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: UI Health (Chicago, IL); UI Health 55th and Pulaski Health Collaborative (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  46. A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    NCT03093116

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest site: University of Chicago (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Massive Bio SYNERGY-AI site (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

    NCT04300556

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Northwestern Memorial Hospital (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

    NCT04317534

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Illinois Cancer Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Olaparib in Patients With HRD Malignant Mesothelioma

    NCT04515836

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Chicago Medical Center (Chicago, IL)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Lung Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.